Cord blood can be used by anyone who needs a stem cell transplant for a blood disorder, immune deficiency, or certain inherited metabolic diseases, whether that person is the baby who donated it, a sibling, or a completely unrelated recipient. Since the first cord blood transplant in 1988, these units have become a routine alternative to bone marrow for patients who need healthy stem cells to replace a diseased blood and immune system.
Conditions Treated With Cord Blood
Cord blood contains blood-forming stem cells that can rebuild a patient’s entire blood and immune system. This makes it a treatment option for a wide range of serious diseases, including cancers of the blood and lymphatic system (leukemia, lymphoma, myeloma), inherited immune deficiencies, hemoglobin disorders like sickle cell disease, and certain genetic metabolic conditions.
For inherited metabolic diseases, cord blood transplants can be especially valuable. Conditions like Hurler syndrome, Krabbe disease, and adrenoleukodystrophy cause progressive nervous system damage and, without treatment, premature death. A cord blood transplant delivers donor-derived cells that can establish themselves in the brain and other organs, stabilizing the disease and preventing further deterioration. For children with these diagnoses, early transplant often offers the best chance at preserving neurological function.
Who Receives Cord Blood: Self, Sibling, or Stranger
Cord blood transplants fall into two categories. Allogeneic transplants use cord blood from a donor, either a related or unrelated one. Autologous transplants use cord blood that was collected and stored at the patient’s own birth. The vast majority of cord blood transplants performed today are allogeneic.
For blood cancers like leukemia, allogeneic transplants are strongly preferred. Donor stem cells provide what’s called a graft-versus-disease effect, where the transplanted immune cells actively help fight any remaining cancer. Using your own stored cord blood doesn’t provide this benefit, which is why leukemia patients typically receive cells from someone else. Autologous stem cell transplants are used most frequently for multiple myeloma and lymphoma, and these usually draw from stem cells collected from the patient’s blood as an adult rather than from stored cord blood.
Siblings are often the first candidates doctors look for when a child needs a transplant. In families with multiple children, roughly 60% of patients have at least one sibling who is a full match, though that percentage varies by family size. A child under five with few or no siblings has about a 43% chance of finding a matched sibling, while an adult with more potential sibling donors sees that number rise to around 68%. When no sibling match exists, public cord blood banks provide units from unrelated donors.
Why Matching Is Easier With Cord Blood
One of cord blood’s biggest advantages over bone marrow is that it requires less precise immune matching between donor and recipient. For a traditional bone marrow or adult stem cell transplant, doctors look for a match at eight specific immune markers, and the best outcomes come from a perfect 8-out-of-8 match. A single mismatch (7 out of 8) is considered acceptable but adds risk.
Cord blood, by contrast, only needs to match on six markers, and a 4-out-of-6 match is the minimum threshold. This significantly expands the pool of potential recipients. Cord blood stem cells are immunologically immature, meaning they’re less likely to attack the recipient’s body even when the match isn’t perfect. This is a major reason cord blood transplants have become a lifeline for patients from ethnic backgrounds that are underrepresented in bone marrow registries, where finding a perfect 8/8 match can be extremely difficult.
Weight and Cell Dose Limits for Adults
Cord blood does have a practical limitation: each unit contains a fixed number of stem cells, and larger patients need more cells for a successful transplant. Guidelines call for a minimum cell dose relative to the recipient’s body weight. For a single cord blood unit, the threshold is roughly 25 million nucleated cells per kilogram of body weight.
This is easy to meet for children but challenging for adults. For a 70-kilogram (about 154-pound) adult, only around 22% of the cord blood units in the U.S. inventory meet the minimum cell dose for a double-unit transplant, where two cord blood units are infused together to provide enough cells. The double-unit approach has made cord blood transplants feasible for many more adults, but it remains true that children and smaller adults have access to a larger share of available units and generally experience better engraftment.
Children vs. Adults: Who Benefits Most
Children have historically been the primary beneficiaries of cord blood transplants, and outcomes are generally stronger in pediatric patients. In a major clinical trial of unrelated cord blood transplants for children with blood cancers, one-year survival was 57.3% and two-year survival was 49.5%. These numbers reflect patients who often had no other transplant option available, and outcomes have continued to improve with better unit selection and supportive care since those trials.
Adults can and do receive cord blood transplants, particularly when no matched bone marrow donor is available. The cell dose challenge is the main hurdle, but double-unit transplants and newer techniques to expand cord blood cells in the lab before infusion have steadily improved adult outcomes. For adults in ethnic minority groups or those with uncommon immune profiles, cord blood may be the only realistic transplant option.
Experimental Uses Beyond Blood Diseases
Beyond its established role in blood and immune disorders, cord blood is being studied for neurological conditions. Early clinical work has used a patient’s own cord blood to treat cerebral palsy caused by oxygen deprivation during birth. In the first human trial of this approach, infusion of the child’s own stored cord blood contributed to meaningful functional improvement in the brain. Research is also exploring cord blood’s potential in other neurological conditions, though these applications remain investigational and are not yet part of standard care.
These experimental uses are one scenario where having your own cord blood privately banked could matter. For established blood cancers and genetic diseases, public cord blood banks and sibling donors are the practical source for the vast majority of transplants performed today.